Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
about
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KITAbl family kinases regulate endothelial barrier function in vitro and in miceA novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemiaLow doses of imatinib induce myelopoiesis and enhance host anti-microbial immunityTargeting tumor-associated macrophages to combat pancreatic cancerChemotherapy- and irradiation-induced bone loss in adults with solid tumorsImatinib enhances functional outcome after spinal cord injuryAnalysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomasImpact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry.Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumorA potential role for colony-stimulating factor 1 in the genesis of the early endometriotic lesion.Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumorsc-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).The colony-stimulating factor-1 (CSF-1) receptor sustains ERK1/2 activation and proliferation in breast cancer cell lines.Identifying mechanism-of-action targets for drugs and probes.Chemical proteomics: terra incognita for novel drug target profiling.CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.miR2Gene: pattern discovery of single gene, multiple genes, and pathways by enrichment analysis of their microRNA regulators.Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo.PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritisExpression of colony-stimulating factor 1 is associated with occurrence of osteochondral change in pigmented villonodular synovitis.Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.Dual tyrosine kinase inhibitors in chronic myeloid leukemia.The Role of Adaptive Immunity in the Efficacy of Targeted Cancer TherapiesDelayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum BiomarkersMast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.Evaluation of the novel USPIO GEH121333 for MR imaging of cancer immune responsesAbelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophagesImatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.Imatinib mesilate for the treatment of gastrointestinal stromal tumour.Gastrointestinal stromal tumors: key to diagnosis and choice of therapy.Disruption of c-Kit Signaling in Kit(W-sh/W-sh) Growing Mice Increases Bone Turnover.Abl tyrosine kinases in T-cell signaling
P2860
Q21142738-E3189E3E-53ED-45E3-BE75-D5B45CB77426Q24316240-2BC30DAB-6901-4923-9949-7AD2BDBCED87Q24685013-715926C2-CC6F-49D0-BDBD-BB7C9BEC2FF6Q27320733-63670AC9-A3E6-477A-9C2D-5009EF56A143Q28076103-B392B67F-22D9-45D8-8375-E9B02A3BFFF5Q28084019-5AA627E1-CA16-4F99-885E-924C88054AB7Q28480537-00300C29-C36F-4073-A923-BB047AF8F715Q33273701-6CD1219F-1B1F-40AC-8423-071392EC1B89Q33304051-64CF23CA-14F1-42D2-85B6-E9BD42DC6459Q33325917-51EC92B2-5029-4841-9E1A-0C373A83D6DBQ33560776-8D0B825C-21FA-41D6-A3E3-097A25998656Q33615748-2F95F2A2-D682-4674-8EAB-4574D797C387Q33636985-550DF2E9-F120-436D-AD77-81E57E91D05CQ33873745-A3B00029-251A-40FE-B567-68EF904510AFQ33897765-19D32AC4-5CBB-4D76-AA2A-2BAA309EF69CQ34028872-BB9B9E5B-9FA2-4517-81E4-2D1BF740F82BQ34077902-E38BD3CA-F65B-445C-BBBA-289A11D29990Q34282670-C842E32D-AE3E-4172-BCB0-C57A4A110886Q34284580-4195C5ED-84F8-4651-9CEC-10E63BB785A4Q34311645-20D03BDB-AB98-4B3F-950A-E72A5E03A54CQ34314927-61B986CD-789B-4D9D-B610-2AC18CC235BFQ34333482-3ACE0E03-D596-4CB4-B2F4-B1F8E4E2367DQ34486262-283EB479-DCA4-45AA-8AFD-518B04174730Q34548738-2882FA77-3391-4376-8A24-0FD1F45736E6Q34577769-38831BBF-9252-4B52-A541-E203DE9E5B19Q35025556-C3EA924B-16CA-408E-8697-4248721ED46EQ35894526-3D161FBE-76DB-46E9-A981-8F0DF446B8ECQ36162943-FC801F2B-A796-4652-AABE-FE18CA082836Q36265601-613A2CFA-AD32-47CA-A73E-A4519593A466Q36535465-D72F2512-24C8-4DC9-9C21-7E9A8DD8D6A5Q36576063-F0B7D601-396C-4BAA-8731-8B63651801D8Q36819873-38679E30-B5AD-45E7-A123-44DC3DDA674CQ36872172-D84B23E7-902F-4625-AF00-002DE2ECA7D9Q36934732-E137AE6F-BD02-44C5-8505-52BBCD75EBE6Q36962682-205F85D2-1F5D-4DCD-9AD0-AEB5286B8788Q36999931-65D2F7CC-E2E8-403C-8DDB-6BE036AF163BQ37142082-4F4143A3-6739-49DD-A85E-CFA118A9A35CQ37176371-8AD66C41-C4CB-4F95-B323-C71B91E8D7C8Q37177303-3342C927-4D88-4AAF-A148-79E56638847BQ37182419-CDCE05A0-E790-4CBA-B0A9-B212BF3CD011
P2860
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
@en
type
label
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
@en
prefLabel
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
@en
P2093
P50
P1433
P1476
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
@en
P2093
Andrea L Dewar
Antony C Cambareri
Bernadette L Miller
Timothy P Hughes
P304
P356
10.1182/BLOOD-2004-10-3967
P407
P577
2005-01-06T00:00:00Z